{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T16:24:27Z","timestamp":1771863867088,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00262-023-03398-3","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T17:02:49Z","timestamp":1677258169000},"page":"2127-2135","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors"],"prefix":"10.1007","volume":"72","author":[{"given":"Fabiana","family":"Perrone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elda","family":"Favari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Maglietta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Verz\u00e8","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Pluchino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Minari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Sabato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Mazzaschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Ronca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessio","family":"Cortellini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Pecci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Cantini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Bersanelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Quaini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello","family":"Tiseo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastiano","family":"Buti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,24]]},"reference":[{"key":"3398_CR1","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.euo.2021.03.001","volume":"4","author":"F Quhal","year":"2021","unstructured":"Quhal F, Mori K, Bruchbacher A, Resch I, Mostafaei H, Pradere B, Schuettfort VM, Laukhtina E, Egawa S, Fajkovic H, Remzi M, Shariat SF, Schmidinger M (2021) First-line immunotherapy-based combinations for metastatic renal cell carcinoma: a systematic review and network meta-analysis. Eur Urol Oncol 4:755\u2013765. https:\/\/doi.org\/10.1016\/j.euo.2021.03.001","journal-title":"Eur Urol Oncol"},{"key":"3398_CR2","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41571-021-00520-1","volume":"18","author":"MJ Grant","year":"2021","unstructured":"Grant MJ, Herbst RS, Goldberg SB (2021) Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. Nat Rev Clin Oncol 18:625\u2013644. https:\/\/doi.org\/10.1038\/s41571-021-00520-1","journal-title":"Nat Rev Clin Oncol"},{"key":"3398_CR3","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3389\/fcell.2020.00162","volume":"8","author":"V Vafaizadeh","year":"2020","unstructured":"Vafaizadeh V, Barekati Z (2020) Immuno-oncology biomarkers for personalized immunotherapy in breast cancer. Front Cell Dev Biol 8:162. https:\/\/doi.org\/10.3389\/fcell.2020.00162","journal-title":"Front Cell Dev Biol"},{"key":"3398_CR4","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/CJI.0000000000000321","volume":"43","author":"F Perrone","year":"2020","unstructured":"Perrone F, Minari R, Bersanelli M, Bordi P, Tiseo M, Favari E, Sabato R, Buti S (2020) The prognostic role of high blood cholesterol in advanced cancer patients treated with immune checkpoint inhibitors. J Immunother 43:196\u2013203. https:\/\/doi.org\/10.1097\/CJI.0000000000000321","journal-title":"J Immunother"},{"key":"3398_CR5","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.2147\/CMAR.S304022","volume":"13","author":"J Tong 3rd","year":"2021","unstructured":"Tong J 3rd, Mao Y, Yang Z, Xu Q, Zheng Z, Zhang H, Wang J, Zhang S, Rong W, Zheng L 3rd (2021) Baseline serum cholesterol levels predict the response of patients with advanced non-small cell lung cancer to immune checkpoint inhibitor-based treatment. Cancer Manag Res 13:4041\u20134053. https:\/\/doi.org\/10.2147\/CMAR.S304022","journal-title":"Cancer Manag Res"},{"key":"3398_CR6","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.2147\/OTT.S315998","volume":"14","author":"H Zhang","year":"2021","unstructured":"Zhang H, Zhao W, Li X, He Y (2021) Cholesterol metabolism as a potential therapeutic target and a prognostic biomarker for cancer immunotherapy. Onco Targets Ther 14:3803\u20133812. https:\/\/doi.org\/10.2147\/OTT.S315998","journal-title":"Onco Targets Ther"},{"key":"3398_CR7","doi-asserted-by":"publisher","first-page":"7209","DOI":"10.3390\/ijms22137209","volume":"22","author":"M Maslyanko","year":"2021","unstructured":"Maslyanko M, Harris RD, Mu D (2021) Connecting cholesterol efflux factors to lung cancer biology and therapeutics. Int J Mol Sci 22:7209. https:\/\/doi.org\/10.3390\/ijms22137209","journal-title":"Int J Mol Sci"},{"key":"3398_CR8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1161\/ATVBAHA.108.179283","volume":"30","author":"L Yvan-Charvet","year":"2010","unstructured":"Yvan-Charvet L, Wang N, Tall AR (2010) Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler Thromb Vasc Biol 30:139\u2013143. https:\/\/doi.org\/10.1161\/ATVBAHA.108.179283","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3398_CR9","first-page":"181","volume-title":"Cholesterol efflux and reverse cholesterol transport","author":"E Favari","year":"2015","unstructured":"Favari E, Chroni A, Tietge QJF, Escol\u00e0-Gil JC, Bernini F (2015) Cholesterol efflux and reverse cholesterol transport. Springer International Publishing, pp 181\u2013206"},{"key":"3398_CR10","doi-asserted-by":"publisher","first-page":"647","DOI":"10.2174\/138945011795378522","volume":"12","author":"D Ye","year":"2011","unstructured":"Ye D, Lammers B, Zhao Y, Meurs I, Van Berkel TJ, Van Eck M (2011) ATP-binding cassette transporters A1 and G1, HDL metabolism, cholesterol efflux, and inflammation: important targets for the treatment of atherosclerosis. Curr Drug Targets 12:647\u2013660. https:\/\/doi.org\/10.2174\/138945011795378522","journal-title":"Curr Drug Targets"},{"key":"3398_CR11","doi-asserted-by":"publisher","first-page":"9186","DOI":"10.3390\/ijms22179186","volume":"22","author":"C Thurm","year":"2021","unstructured":"Thurm C, Schraven B, Kahlfuss S (2021) ABC transporters in T cell-mediated physiological and pathological immune responses. Int J Mol Sci 22:9186. https:\/\/doi.org\/10.3390\/ijms22179186","journal-title":"Int J Mol Sci"},{"key":"3398_CR12","doi-asserted-by":"publisher","first-page":"6354","DOI":"10.1038\/ncomms7354","volume":"6","author":"D Sag","year":"2015","unstructured":"Sag D, Cekic C, Wu R, Linden J, Hedrick CC (2015) The cholesterol transporter ABCG1 links cholesterol homeostasis and tumour immunity. Nat Commun 6:6354. https:\/\/doi.org\/10.1038\/ncomms7354","journal-title":"Nat Commun"},{"key":"3398_CR13","doi-asserted-by":"publisher","first-page":"15663","DOI":"10.1038\/ncomms15663","volume":"8","author":"B Castella","year":"2017","unstructured":"Castella B, Kopecka J, Sciancalepore P, Mandili G, Foglietta M, Mitro N, Caruso D, Novelli F, Riganti C, Massaia M (2017) The ATP-binding cassette transporter A1 regulates phosphoantigen release and V\u03b39V\u03b42 T cell activation by dendritic cells. Nat Commun 8:15663. https:\/\/doi.org\/10.1038\/ncomms15663","journal-title":"Nat Commun"},{"key":"3398_CR14","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/s41577-021-00618-8","volume":"22","author":"D Zhivaki","year":"2022","unstructured":"Zhivaki D, Kagan JC (2022) Innate immune detection of lipid oxidation as a threat assessment strategy. Nat Rev Immunol 22:322\u2013330. https:\/\/doi.org\/10.1038\/s41577-021-00618-8","journal-title":"Nat Rev Immunol"},{"key":"3398_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"3398_CR16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1056\/NEJMoa1001689","volume":"364","author":"AV Khera","year":"2011","unstructured":"Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ (2011) Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364:127\u2013135. https:\/\/doi.org\/10.1056\/NEJMoa1001689","journal-title":"N Engl J Med"},{"key":"3398_CR17","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/FJC.0000000000000573","volume":"71","author":"E Favari","year":"2018","unstructured":"Favari E, Thomas MJ, Sorci-Thomas MG (2018) High-density lipoprotein functionality as a new pharmacological target on cardiovascular disease: unifying mechanism that explains high-density lipoprotein protection toward the progression of atherosclerosis. J Cardiovasc Pharmacol 71:325\u2013331. https:\/\/doi.org\/10.1097\/FJC.0000000000000573","journal-title":"J Cardiovasc Pharmacol"},{"key":"3398_CR18","doi-asserted-by":"publisher","first-page":"28634","DOI":"10.1074\/jbc.M003407200","volume":"275","author":"AE Bortnick","year":"2000","unstructured":"Bortnick AE, Rothblat GH, Stoudt G, Hoppe KL, Royer LJ, McNeish J, Francone OL (2000) The correlation of ATP-binding cassette 1 mRNA levels with cholesterol efflux from various cell lines. J Biol Chem 275:28634\u201328640. https:\/\/doi.org\/10.1074\/jbc.M003407200","journal-title":"J Biol Chem"},{"key":"3398_CR19","doi-asserted-by":"publisher","first-page":"11067","DOI":"10.1021\/bi901564g","volume":"48","author":"E Favari","year":"2009","unstructured":"Favari E, Calabresi L, Adorni MP, Jessup W, Simonelli S, Franceschini G, Bernini F (2009) Small discoidal pre-beta1 HDL particles are efficient acceptors of cell cholesterol via ABCA1 and ABCG1. Biochemistry 48:11067\u201311074. https:\/\/doi.org\/10.1021\/bi901564g","journal-title":"Biochemistry"},{"key":"3398_CR20","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.atherosclerosis.2015.08.007","volume":"242","author":"F Zimetti","year":"2015","unstructured":"Zimetti F, Favari E, Cagliero P, Adorni MP, Ronda N, Bonardi R, Gomaraschi M, Calabresi L, Bernini F, Guardamagna O (2015) Cholesterol trafficking-related serum lipoprotein functions in children with cholesteryl ester storage disease. Atherosclerosis 242:443\u2013449. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.08.007","journal-title":"Atherosclerosis"},{"key":"3398_CR21","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1194\/jlr.P076463","volume":"58","author":"F Zimetti","year":"2017","unstructured":"Zimetti F, De Vuono S, Gomaraschi M, Adorni MP, Favari E, Ronda N, Ricci MA, Veglia F, Calabresi L, Lupattelli G (2017) Plasma cholesterol homeostasis, HDL remodeling and function during the acute phase reaction. J Lipid Res 58:2051\u20132060. https:\/\/doi.org\/10.1194\/jlr.P076463","journal-title":"J Lipid Res"},{"key":"3398_CR22","doi-asserted-by":"publisher","first-page":"292","DOI":"10.2174\/138920112799095383","volume":"13","author":"I Zanotti","year":"2012","unstructured":"Zanotti I, Favari E, Bernini F (2012) Cellular cholesterol efflux pathways: impact on intracellular lipid trafficking and methodological considerations. Curr Pharm Biotechnol 13:292\u2013302. https:\/\/doi.org\/10.2174\/138920112799095383","journal-title":"Curr Pharm Biotechnol"},{"key":"3398_CR23","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3390\/biomedicines8120625","volume":"8","author":"A Di Costanzo","year":"2020","unstructured":"Di Costanzo A, Ronca A, D\u2019Erasmo L, Manfredini M, Baratta F, Pastori D, Di Martino M, Ceci F, Angelico F, Del Ben M, Pavanello C, Turri M, Calabresi L, Favari E, Arca M (2020) HDL-mediated cholesterol efflux and plasma loading capacities are altered in subjects with metabolically- but not genetically driven non-alcoholic fatty liver disease (NAFLD). Biomedicines 8:625. https:\/\/doi.org\/10.3390\/biomedicines8120625","journal-title":"Biomedicines"},{"key":"3398_CR24","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/MOL.0b013e328352c4dd","volume":"23","author":"HC Prosser","year":"2012","unstructured":"Prosser HC, Ng MKC, Bursill CA (2012) The role of cholesterol efflux in mechanisms of endothelial protection by HDL. Curr Opin Lipidol 23:182\u2013189. https:\/\/doi.org\/10.1097\/MOL.0b013e328352c4dd","journal-title":"Curr Opin Lipidol"},{"key":"3398_CR25","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1136\/annrheumdis-2012-202914","volume":"73","author":"N Ronda","year":"2014","unstructured":"Ronda N, Favari E, Borghi MO, Ingegnoli F, Gerosa M, Chighizola C, Zimetti F, Adorni MP, Bernini F, Meroni PL (2014) Impaired serum cholesterol efflux capacity in rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis 73:609\u2013615. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202914","journal-title":"Ann Rheum Dis"},{"key":"3398_CR26","doi-asserted-by":"publisher","first-page":"e13766","DOI":"10.1111\/eci.13766","volume":"16","author":"Q Ying","year":"2022","unstructured":"Ying Q, Ronca A, Chan DC, Pang J, Favari E, Watts GF (2022) Effect of a PCSK9 inhibitor and a statin on cholesterol efflux capacity: a limitation of current cholesterol-lowering treatments? Eur J Clin Invest 16:e13766. https:\/\/doi.org\/10.1111\/eci.13766","journal-title":"Eur J Clin Invest"},{"key":"3398_CR27","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.cmet.2019.02.016","volume":"29","author":"P Goossens","year":"2019","unstructured":"Goossens P, Rodriguez-Vita J, Etzerodt A, Masse M, Rastoin O, Gouirand V, Ulas T, Papantonopoulou O, Van Eck M, Auphan-Anezin N, Bebien M, Verthuy C, Vu Manh TP, Turner M, Dalod M, Schultze JL, Lawrence T (2019) Membrane cholesterol efflux drives tumor-associated macrophage reprogramming and tumor progression. Cell Metab 29:1376\u20131389. https:\/\/doi.org\/10.1016\/j.cmet.2019.02.016","journal-title":"Cell Metab"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03398-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-023-03398-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03398-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T12:05:45Z","timestamp":1686657945000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-023-03398-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,24]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["3398"],"URL":"https:\/\/doi.org\/10.1007\/s00262-023-03398-3","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,24]]},"assertion":[{"value":"20 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alessio Cortellini received speaker fees and grant consultancies by AstraZeneca, MSD, BMS, Roche, Novartis and EISAI. Luca Cantini is granted by ESMO with an ESMO Translational Research Fellowship. Any views, opinions, findings, conclusions or recommendations expressed in this material are those solely of the author(s) and do not necessarily reflect those of ESMO. Melissa Bersanelli received research funding (Institutional) from Roche S.p.A., Pfizer, Seqirus UK, Novartis, Bristol Myers Squibb (BMS), AstraZeneca, Sanofi Genzyme; honoraria as a speaker at scientific events and for advisory role (personal fees) from BMS, MSD, Novartis, AstraZeneca, Pierre Fabre, Pfizer, IPSEN; personal fees for copyright transfer from SciClone Pharmaceuticals, IPSEN, Pierre Fabre, MSD, Sanofi Genzyme. Marcello Tiseo: He received honoraria for advisory boards and\/or speakers\u2019 fee for AstraZeneca, Pfizer, Eli-Lilly, BMS, Novartis, Roche, MSD, Boehringer Ingelheim, Otsuka, Takeda, Pierre Fabre, Amgen and Merck, Sanofi. Research Grants from AstraZeneca and Boehringer Ingelheim. Sebastiano Buti: He received honoraria as a speaker at scientific events and advisory role by BMS, Pfizer, MSD, Ipsen, AstraZeneca and Novartis; he also received research funding from Novartis. The remaining authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors affirm that human research participants provided informed consent for publication of individual\u2019s details.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Area Vasta Emilia Nord protocol (Date September 21, 2021\/No37649).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}